Key TakeawaysBiogen is diversifying its pipeline to reduce reliance on blockbuster drugs, launching therapies in Alzheimer’s, Friedreich Ataxia, postpartum depression, and ALS.The company achieved significant cost savings through organizational redesign, supporting its strategic shift beyond multiple sclerosis treatments.Biogen’s late-stage pipeline includes 10 phase three programs and five new product launches, though early-stage R&D needs strengthening.The […]
